Retinal Vein Occlusion: Long-Term Management

High blood pressure is the single most common risk factor for RVO, and uncontrolled hypertension can also lead to hypertensive retinopathy. Other significant contributors include diabetes, elevated cholesterol, and atherosclerosis (hardening of the arteries). These conditions damage blood vessel walls over time, making the retinal veins more susceptible to compression and clot formation. Managing these systemic conditions is essential for reducing the risk of further vascular events, including retinal artery occlusion and stroke.

Open-angle glaucoma and elevated eye pressure have been associated with an increased risk of RVO, particularly CRVO. The elevated pressure within the eye may contribute to compression of the central retinal vein as it passes through the optic nerve head. A thorough eye examination can help identify these additional risk factors early.

In younger patients or those without typical cardiovascular risk factors, an underlying clotting disorder (thrombophilia) may be the cause. Conditions such as hyperhomocysteinemia, antiphospholipid syndrome, and Factor V Leiden can increase the tendency for blood clots to form. Our retina specialists may recommend blood testing in collaboration with your primary care physician or a hematologist to evaluate for these conditions.

The number of injections varies widely depending on the type and severity of the occlusion and how your eye responds to treatment. Many patients receive monthly injections for the first several months, then transition to a treat-and-extend protocol where the interval between injections is gradually lengthened. Some patients may need treatment for one to two years or longer, while others with BRVO may require fewer injections overall. Your treatment schedule is tailored to your individual response at each follow-up visit.

With timely and consistent treatment, many patients with RVO can maintain or improve their vision. Patients with BRVO tend to have a more favorable outlook, with a significant number recovering good functional vision. CRVO outcomes are more variable, particularly in ischemic cases. Consistent follow-up appointments and adherence to your treatment plan are the most important factors in achieving the best possible long-term result.

Yes, RVO can recur in the same eye or develop in the other eye. Studies suggest that approximately 5 to 15 percent of patients experience a recurrence or a new occlusion within several years. Managing cardiovascular risk factors, particularly high blood pressure, is the most effective way to reduce this risk. Regular retinal examinations allow us to detect any new changes early.

RVO is strongly associated with hypertension, diabetes mellitus, hyperlipidemia, and cardiovascular disease. Less commonly, it can be linked to blood clotting disorders, inflammatory conditions, and autoimmune diseases. Because RVO may be the first sign of an undiagnosed systemic condition, we often recommend a thorough medical evaluation, including bloodwork, after diagnosis. Patients with RVO also have a modestly increased risk of future stroke and heart disease, making systemic vascular assessment an important step.

You should see a retina specialist as soon as possible after any sudden, painless change in vision. Early diagnosis allows treatment to begin before permanent damage to the macula occurs. If you have already been diagnosed with RVO, keeping all scheduled follow-up appointments is essential, even when your vision feels stable, because macular edema can recur silently. Patients with risk factors such as uncontrolled blood pressure or diabetes should also discuss regular retinal screening with fluorescein angiography with their eye doctor.